Emerging retatrutide, a dual -action drug targeting both GLP-1 and GIP receptors, is generating considerable interest within the healthcare community. Initial clinical studies have demonstrated substantial https://charlielmkd457518.fitnell.com/82285760/a-new-promise-for-weight-management